Please ensure Javascript is enabled for purposes of website accessibility

Gene Therapy Biotech Passage Bio IPOs

By Brian Orelli, PhD – Updated Feb 28, 2020 at 4:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage biotech raised $216 million.

Passage Bio (PASG -6.87%) picked a difficult week to make its public debut, with the market in the midst of a correction driven by fears that the COVID-19 coronavirus will have a significant economic impact.

The gene therapy company raised $216 million in its initial public offering, which it priced at $18 per share. Shares of Passage Bio were up almost 20% at 2:19 p.m. EST Friday.

A depiction of human DNA.

Image source: Getty Images.

The company, which was spun out of the gene therapy program at the University of Pennsylvania, has three therapies in its pipeline. PBGM01 is being developed as a treatment for GM1 gangliosidosis, a nervous system disease caused by mutations in the GLB1 gene. PBFT02 will be studied in patients with frontotemporal dementia who have a mutation in the granulin gene. The third program, PBKR03, is being developed for infantile Krabbe disease, which is caused by mutations in the GALC gene that lead to damage in both the central  and peripheral nervous systems.

None of the treatments are in the clinic yet, but Passage Bio expects to treat the first patients in a clinical trial for PBGM01 in the second half of this year. Clinical trials for the other two programs are expected to start in the first half of next year.

The biotech is currently running a natural history study in patients with GM1 gangliosidosis to determine which outcomes it should measure in its clinical trial of PBGM01.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Passage Bio, Inc. Stock Quote
Passage Bio, Inc.
PASG
$1.22 (-6.87%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.